65,437 trials
Hemophilia · Hemophilic Arthropathy
Primary: Pain (Visual Analogue Scale) and Change From Baseline at 1, 2, 3 &6 Months — 5.0; 4.1; 2.5; 1.8 scores on a scale — p=<0.05
Bone Deficiency, Posterior Maxillae
Primary: Lateral Wall Thickness — 161 mm
Body Fat Disorder
Primary: Percentage of Pre-treatment Images Correctly Identified — 85.2 percent correctly identified images
Tooth Loss
Primary: Implant Survival Rate at 12 Months After Implant Placement — 92.68 percentage of participants
Sun-induced Wrinkles
Primary: Wrinkles' Severity (Forehead) — 2.31; 2.66; 2.60; 1.78 units on a scale — p=<0.05
MItochondrial Myopathies
Primary: Change of Peak Workload (in Watts/kg) During Exercise Testing — 0.0090; 0.020; -0.0300; 0.1050 Watts/kg — p=0.7321
Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
Primary: Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders). — 60; 34 Participants
Breast Cancer
Primary: Best Overall Response — 0; 0; 6; 12 participants
Cannabis Abuse · Cannabis Dependence
Primary: Cannabis Use — 55.89; 63.10 Percentage of use days
Vaccine Response Impaired
Primary: Change in Skin Tissue Response to a Vaccine — 39.0; 36.1; 21.5; 11.8 Total number of CD1a+ cells (5hpf)
Knee Injuries · ACL Injury
Primary: Numeric Pain Rating Scale (NPRS) Pain Score — 5.2; 5.3; 5.0; 5.6 score on a scale
Dental Plaque
Primary: Change in Whole Mouth Rustogi Modified Navy Plaque Index (RMNPI) Score From Pre-Brushing to Post-Brushing (When Prototype Power Toothbrush [PTB] Was Used in 'Gumline'…
Low Back Pain · Chronic Pain
Primary: The Change in Weekly (ie, 7-day Average) Pain Score at the End of Double-blind, Randomized Treatment Period, Relative to the Weekly Score at the End of Titration…
Dyskinesia · Levodopa Induced Dyskinesia (LID) · Parkinson's Disease (PD)
Primary: Number of Participants With Reported AEs and Safety-Related Study Drug Discontinuations — 57; 70; 23; 55 Participants
Bronchioloalveolar Carcinoma · Large Cell Lung Carcinoma · Lung Adenocarcinoma
Primary: PFS (Progression Free Survival) — 8; 20 months